Pharmacokinetics, Safety and Tolerability of Moxifloxacin, a Novel 8-Methoxyfluoroquinolone, after Repeated Oral Administration
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
To investigate the pharmacokinetics, safety and tolerability of moxifloxacin after single and repeated doses.
Design and setting
This series comprised 3 separate placebo-controlled studies, 2 studies with a randomised crossover design (up to 400 mg/day) and 1 study with a group comparison design (600mg once daily).
Patients and participants
Healthy male volunteers were included in these studies.
Participants received 5-day treatment courses of moxifloxacin 100mg (n = 8) or 200mg (n = 8) twice daily or 400mg once daily (n = 7), or a 10-day treatment course of moxifloxacin 600mg once daily (n = 7). Pharmacokinetics were characterised after the first dose (24-hour profile) and the last dose (96-hour profile), with additional trough and peak measurements during the courses.
All treatments were well tolerated. No clinically relevant changes in the standard laboratory tests, vital signs or ECG were observed. Minimum plasma concentrations required to inhibit 90% of susceptible micro-organisms (e.g. 0.125 mg/L for Streptococcus pneumoniae) were attained rapidly and exceeded until the end of treatment. Repeated doses of 100 and 200mg twice daily and 400mg once daily resulted in stable trough and peak concentrations within 3 days of the first dose. The concentrations at steady state were moderately higher (approximately 30% for 400mg once daily) than after the first dose. Steady-state peak concentrations were between 0.9 mg/L (100mg twice daily) and 5.7 mg/L (600mg once daily). The terminal elimination half-life was 14 to 15 hours, supporting once daily administration of the drug. Accumulation ratios ranged between 87% for the lowest dosage and 111% after repeated doses of 600mg once daily, indicating the absence of clinically relevant accumulation due to non-linear pharmacokinetics. Across the studies, the average exposure after single and repeated doses was proportional to the dose administered.
These studies indicate that, based on the safety profile and the pharmacokinetic behaviour of moxifloxacin, a dosage regimen of 400mg given once daily should be effective and well tolerated for the treatment of various infections.
- Jacobs E, Dalhoff A, Branner H. Efficacy of BAY 12-8039 in Mycoplasma pneumoniae infected guinea pigs [abstract no. F17]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 Sep 15–18; New Orleans, Louisiana: 102
- Stass H, Kubitza D. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. J Antimicrob Chemother 1999; 43 Suppl. B: 83–90 CrossRef
- Ballow C, Lettieri J, Agarwal V, et al. Absolute bioavailability of moxifloxacin. Clin Ther 1999; 21: 513–22 CrossRef
- Stass H, Ochmann K. Study to evaluate the interaction between BAY 12-8039 and ranitidine [abstract no. 3357]. 20th International Congress of Chemotherapy; 1997 Jun 29–Jul 3; Sydney, Australia: 108
- Stass H, Kubitza D. Effects of dairy products on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers. Clin Pharmacokinet 2001; 40 Suppl. 1: 33–38 CrossRef
- Stass H, Kubitza D, Unger S. The effect of food on the oral bioavailability of moxifloxacin in healthy male volunteers. Moxifloxacin in Clinical Practice 2000; 3: 15–23
- Stass H, Siefert M, Steinke W. 1998. Moxifloxacin — review of clinical pharmacokinetics: distribution and tissue penetration. 6th International Symposium on New Quinolones; 1998 Nov 15–18; Denver, Colorado, USA: 133
- Kern A, Kanhai W, Fröhde R, et al. BAY 12-8039, a new 8-methoxy-quinolone: metabolism in rat, monkey and man [abstract no. F23]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 Sep 15–18; New Orleans, Louisiana: 103
- Wise R. Areview of the clinical pharmacology of moxifloxacin, a new 8-methoxyquinolone, and its potential relation to therapeutic efficacy. Clin Drag Invest 1999; 17: 365–87 CrossRef
- Stass H, Kubitza D, Schühly U. BAY 12-8039, a new 8-methoxy-quinolone, pharmacokinetics, safety and tolerability of single ascending intravenous doses in healthy male volunteers [abstract no. F153]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28–Oct 1; Toronto, Ontario: 172
- Stass H, Dalhoff A. Determination of BAY 12-8039, a new 8-methoxyquinolone, in human body fluids by high-performance liquid chromatography with fluorescence detection using on-column focusing. J Chromatogr B Biomed Sci Appl 1997; 702: 163–74 CrossRef
- Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker Inc., 1982
- Kuhlmann J, Schäfer HG, Beermann D. Clinical pharmacology. In: Kuhlmann J, Dalhoff A, Zeiler HJ, editors. Handbook of experimental pharmacology: quinolone antibacterials. Berlin: Springer Verlag, 1998; vol. 127: 339–406 CrossRef
- Efthymiopoulos C, Bramer SL, Maroli A. Pharmacokinetics of grepafloxacin after oral administration of single and repeat doses in healthy young males. Clin Pharmacokinet 1997; 33 Suppl. 1: 1–8 CrossRef
- Frydman MA, Le Roux Y, Lefebvre MA, et al. Pharmacokinetics of Pefloxacin after repeated intravenous and oral administration (400 mg bid) in young healthy volunteers. J Antimicrob Chemother 1986; 17 Suppl. B: 65–79 CrossRef
- Sullivan JT, Woodruff M, Lettieri J, et al. Pharmacokinetics of a once-daily oral dose of moxifloxacin (BAY 12-8039), a new enantiomerically pure 8-methoxyquinolone. Antimicrob Agents Chemother 1999; 43(11): 2793–7
- Kubitza D, Stass H, Wingender W, et al. Bay 12-8039. A new 8-methoxyquinolone: safety, tolerability and steady-state pharmacokinetics in healthy male volunteers. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy [abstract no. F-025]; 1996 Sep 15–18; New Orleans, Louisiana: 100
- Stass H, Schühly U, Wingender W. Pharmacokinetics, safety and tolerability of 600mg BAY 12-8039 administered once daily over 10 days [abstract no. P387]. 8th European Congress of Clinical Microbiology and Infectious Diseases; 1997 May 25–28; Lausanne, Switzerland. Clin Microbiol Infection 1997; 4 Suppl. 2: 87
- Pharmacokinetics, Safety and Tolerability of Moxifloxacin, a Novel 8-Methoxyfluoroquinolone, after Repeated Oral Administration
Volume 40, Issue 1 Supplement, pp 1-9
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors